Cognitive Impairment - Pipeline Review, H2 2015 Now Available at iData Insights Cognitive Impairment - Pipeline Review, H2 2015 Summary Global Markets Direct s, Cognitive Impairment Pipeline Review, H2 2015 , provides an overview of the Cognitive Impairment s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Cognitive Impairment, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cognitive Impairment and special features on latestage and discontinued projects. Global Markets Direct s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Cognitive Impairment - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Cognitive Impairment and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Cognitive Impairment products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Cognitive Impairment pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies Identify and understand important and diverse types of therapeutics under development for Cognitive Impairment Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cognitive Impairment pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Browse Complete Report with TOC @ http://www.idatainsights.com/reports-landingpage.php?id=124187/cognitive-impairment-pipeline-review-h2-2015 To Get Sample Copy of Report visit @ http://www.idatainsights.com/reports-landingpage.php?id=124187/cognitive-impairment-pipeline-review-h2-2015 Table of Contents Table of Contents 2 List of Tables 7 List of Figures 9 Introduction 10 Global Markets Direct Report Coverage 10 Cognitive Impairment Overview
1
11 Therapeutics Development 12 Pipeline Products for Cognitive Impairment - Overview 12 Pipeline Products for Cognitive Impairment - Comparative Analysis 13 Cognitive Impairment - Therapeutics under Development by Companies 14 Cognitive Impairment - Therapeutics under Investigation by Universities/Institutes 19 Cognitive Impairment - Pipeline Products Glance 21 Late Stage Products 21 Clinical Stage Products 22 Early Stage Products 23 Cognitive Impairment - Products under Development by Companies 24 Cognitive Impairment - Products under Investigation by Universities/Institutes 31 Cognitive Impairment - Companies Involved in Therapeutics Development 32 AbbVie Inc. 32 Actinogen Limited 33 Addex Therapeutics Ltd 34 Amarantus Bioscience Holdings, Inc. 35 Astellas Pharma Inc. 36 AstraZeneca Plc 37 Avineuro Pharmaceuticals, Inc. 38 Avraham Pharmaceuticals Ltd. 39 Boehringer Ingelheim GmbH 40 Bristol-Myers Squibb Company 41 Cardax Pharmaceuticals, Inc. 42 CereSpir Incorporated 43 Cognition Therapeutics, Inc. 44 D-Pharm Ltd. 45 Eisai Co., Ltd. 46 Eli Lilly and Company 47 Evotec AG 48 F. Hoffmann-La Roche Ltd. 49 FORUM Pharmaceuticals Inc. 50 H. Lundbeck A/S 51 Heptares Therapeutics Limited 52 Impel NeuroPharma, Inc.
2
53 Intra-Cellular Therapies, Inc. 54 Iproteos S.L. 55 Merck & Co., Inc. 56 Mnemosyne Pharmaceuticals, Inc. 57 Neuralstem, Inc. 58 Neuron Biopharma SA 59 Octapharma AG 60 Omeros Corporation 61 Pacific Northwest Biotechnology, LLC 62 Panacea Pharmaceuticals, Inc. 63 Pfizer Inc. 64 Pherin Pharmaceuticals, Inc. 65 Sage Therapeutics 66 Saniona AB 67 Shire Plc 68 Siena Biotech S.p.A. 69 SK Biopharmaceuticals Co., Ltd. 70 Sunovion Pharmaceuticals Inc. 71 Suven Life Sciences Ltd. 72 Takeda Pharmaceutical Company Limited 73 Teva Pharmaceutical Industries Limited 74 Upsher-Smith Laboratories, Inc. 75 Vanda Pharmaceuticals Inc. 76 Vicore Pharma AB 77 Virogenomics, Inc. 78 Cognitive Impairment - Therapeutics Assessment 79 Assessment by Monotherapy Products 79 Assessment by Target 80 Assessment by Mechanism of Action 88 Assessment by Route of Administration 95 Assessment by Molecule Type 98 Drug Profiles 101 A-431404 - Drug Profile 101 ADX-92639 - Drug Profile 102 AN-761 - Drug Profile 103 AP-61 - Drug Profile
3
104 AQW-051 - Drug Profile 105 ASP-4345 - Drug Profile 106 ASP-5736 - Drug Profile 107 AUT-1 - Drug Profile 108 AUT-6 - Drug Profile 109 AUT-9 - Drug Profile 110 AVL-3288 - Drug Profile 111 AVN-211 - Drug Profile 112 BAN-2401 - Drug Profile 113 BCA-909 - Drug Profile 115 BI-409306 - Drug Profile 117 BNC-375 - Drug Profile 119 C-21 - Drug Profile 120 CDX-085 - Drug Profile 122 CSP-1103 - Drug Profile 124 CT-0093 - Drug Profile 126 DAOI-B - Drug Profile 127 DP-NDD - Drug Profile 128 Drug to Agonize Muscarinic M1 and M4 Receptors for Psychosis and Neurologic Diseases - Drug Profile 129 Drugs to Inhibit Matrix Metalloproteinase for Dementia and Cognitive Impairment - Drug Profile 130 DSP-3748 - Drug Profile 131 E-1R - Drug Profile 132 eltoprazine - Drug Profile 133 encenicline hydrochloride - Drug Profile 135 erteberel - Drug Profile 138 EVT-501 - Drug Profile 139 HTL-9936 - Drug Profile 140 IB-AD - Drug Profile 141 IC-041 - Drug Profile 142 idursulfase - Drug Profile 143 immune globulin (human) - Drug Profile 145 insulin (human) - Drug Profile 148 IPR-001 - Drug Profile
4
149 IPR-088 - Drug Profile 150 IPR-19 - Drug Profile 151 irdabisant - Drug Profile 152 ITI-214 - Drug Profile 153 JAY-22233 - Drug Profile 154 ladostigil tartrate - Drug Profile 156 levetiracetam - Drug Profile 158 LS-1137 - Drug Profile 159 LUAF-64280 - Drug Profile 160 LY-3002813 - Drug Profile 161 NPS-0158 - Drug Profile 162 NS-9283 - Drug Profile 163 NSI-189 - Drug Profile 165 NSP-0163 - Drug Profile 167 NST-0037 - Drug Profile 168 NST-0076 - Drug Profile 169 NST-0078 - Drug Profile 170 O-1966 - Drug Profile 171 PAN-811 - Drug Profile 172 PF-04958242 - Drug Profile 174 PH-15 - Drug Profile 176 PNU-120596 - Drug Profile 177 RO-4938581 - Drug Profile 178 roflumilast - Drug Profile 179 RTL-551 - Drug Profile 182 SEN-15924 - Drug Profile 184 sepranolone - Drug Profile 185 SKL-15508 - Drug Profile 188 SKL-A4R - Drug Profile 189 Small Molecule 1 for Cognitive Impairment - Drug Profile 190 Small Molecule 10 for Cognitive Impairment - Drug Profile 191 Small Molecule 11 for Cognitive Impairment - Drug Profile 192 Small Molecule 12 for Cognitive Impairment - Drug Profile 193 Small Molecule 2 for Cognitive Impairment - Drug Profile 194 Small Molecule 3 for Cognitive Impairment - Drug Profile
5
195 Small Molecule 4 for Cognitive Impairment - Drug Profile 196 Small Molecule 5 for Cognitive Impairment - Drug Profile 197 Small Molecule 6 for Cognitive Impairment - Drug Profile 198 Small Molecule 7 for Cognitive Impairment - Drug Profile 199 Small Molecule 8 for Cognitive Impairment - Drug Profile 200 Small Molecule to Agonize Neuronal Acetylcholine Receptor Subunit Alpha-7 for Central Nervous System - Drug Profile 201 Small Molecule to Antagonize GPR12 for Obesity, Cognitive Impairments and Motor Disorders - Drug Profile 202 Small Molecule to Antagonize Histamine 3 Receptor for Cognition - Drug Profile 203 Small Molecule to Antagonize nAChR Alpha-4 Beta-2 for CNS Disorders - Drug Profile 204 Small Molecule to Inhibit Glutamate Carboxypeptidase 2 for Cognitive Impairment and Memory Impairment Drug Profile 205 Small Molecule to Target GPR151 for CNS Diseases - Drug Profile 206 Small Molecule to Target MAS1 for Cognitive Impairments, Blood Pressure Abnormalities and Colon Cancer Drug Profile 207 Small Molecules for Cognitive Impairment Associated with Schizophrenia - Drug Profile 208 Small Molecules to Agonize Alpha7 Acetylcholine Receptor for Cognitive Impairment - Drug Profile 209 Small Molecules to Agonize Beta-1 Adrenergic Receptor for Cognitive Impairment - Drug Profile 210 Small Molecules to Agonize Dopamine D1 Receptor for Cognitive Impairment Associated with Schizophrenia Drug Profile 211 Small Molecules to Agonize GABA alpha 5 for Cognitive Impairment - Drug Profile 212 Small Molecules to Agonize GABAA Receptor for Cognitive Impairment - Drug Profile 213 Small Molecules to Agonize NMDA2B for CIAS - Drug Profile 214 Small Molecules to Antagonize 5-HT6 Receptors for Cognitive Impairment - Drug Profile 216 SUVN-501 - Drug Profile 218 SUVN-502 - Drug Profile 219 SUVN-507 - Drug Profile 221 SUVN-512 - Drug Profile 222 SUVN-976 - Drug Profile 223 TAK-058 - Drug Profile 224 TAK-915 - Drug Profile 225 tropisetron hydrochloride - Drug Profile 226 UE-2343 - Drug Profile 227 VU-0092273 - Drug Profile 228 xamoterol fumarate - Drug Profile 229 Cognitive Impairment - Recent Pipeline Updates 230 Cognitive Impairment - Dormant Projects
6
258 Cognitive Impairment - Discontinued Products 265 Cognitive Impairment - Product Development Milestones 266 Featured News & Press Releases 266 Appendix 276 Methodology 276 Coverage 276 Secondary Research 276 Primary Research 276 Expert Panel Validation 276 Contact Us 276 Disclaimer 277 Read More @ http://www.idatainsights.com/reports-landing-page.php?id=124187/cognitive-impairment-pipelinereview-h2-2015 About Us: iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.
Contact Us: iData Insights Tel: 1-866-237-2965 Web: http://www.idatainsights.com Email: info@idatainsights.com
About iData Insights We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future projects.
7